13 February 2017 - PHARMAC has published the minutes from the 3-4 November meeting.

The PTAC recommended:

• Adalimumab (Humira) for hidradenitis suppurativa be listed with a low priority
  
• Pembrolizumab (Keytruda) for use as monotherapy be funded with low priority for the second or third-line treatment of locally advanced, or metastatic, unresectable non-small-cell lung cancer expressing PD-L1 at a level of equal or greater than 1%.
  

Read PHARMAC minutes